SHANGHAI, January 31^st, 2023 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd (“Roche”) to evaluate CARsgen’s investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance globally, in combination with atezolizumab, Roche’s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma . Under the terms of the agreement, Roche will be responsible for operation and conduct of the trial while both companies co-share the costs of the AB011 treatment arms in the study. As part of the clinical collaboration, CARsgen’s proprietary CLDN18.2 IHC test kit, which has showed excellent specificity and sensitivity profiles, will be applied to evaluate CLDN18.2 expression in the gastric cancer patients.

SHANGHAI, January 20, 2023 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a poster presentation highlighting the Phase 1 preliminary results of a recombinant humanized anti-claudin18.2 monoclonal antibody (AB011), as monotherapy and combination therapy, for patients with advanced solid tumors was presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (“ASCO GI”), in San Francisco, California, during January 19-21, 2023.

SHANGHAI, January 16, 2023 — CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, and Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (Huadong Medicine; SZ: 000963)，today announced a collaboration for the commercialization of CARsgen’s BCMA CAR-T product CT053 in mainland China.

 SHANGHAI, December 28, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Company and the State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, have jointly developed a new technology that can significantly increase antitumor activities of T cells. The study was recently published on Molecular Therapy.

SHANGHAI, December 12, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Hematology (the “ASH”) Annual Meeting, the Company presented a poster with the results of the phase II LUMMICAR STUDY 1 clinical trial of zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053, an autologous CAR T-cell product candidate against BCMA) in Chinese patients with relapsed/refractory multiple myeloma (R/R MM). This poster reports for the first time the pivotal phase II safety and efficacy data of LUMMICAR STUDY 1.

SHANGHAI, October 31, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Sylvie Peltier (“Dr. Peltier”) has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31^st, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company’s regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally.

SHANGHAI, October 18, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for zevorcabtagene autoleucel (“zevor-cel,” R&D code: CT053), a fully human, autologous BCMA CAR T-cell therapy for the treatment of relapsed and/or refractory multiple myeloma (R/R MM).

SHANGHAI, September 21, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 7th Annual CAR-TCR Summit, in Boston, Massachusetts, the Company gave an oral presentation on the North America Phase 2 clinical trial of zevorcabtagene autoleucel (“zevor-cel”, R&D code: CT053), an autologous CAR T-cell product candidate against BCMA. This multi-center, open-label, Phase 1b/2 study (NCT03915184) is being conducted to evaluate the safety and efficacy in North American patients with relapsed and/or refractory multiple myeloma (R/R MM).

SHANGHAI, September 2, 2022 — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the company’s Current Good Manufacturing Practice (CGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America (“The RTP GMP Manufacturing Facility”) has started GMP production of autologous CAR T-cell products and successfully released the first GMP batch for the clinical trials.